Epirubicin Clinical Trials
19 recruitingDrug
Phase 212Phase 35Phase 42Phase 12
Showing 1–19 of 19 trials
Recruiting
Phase 3
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC2,400 enrolled268 locationsNCT06966700
Recruiting
Phase 3
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
Resectable HER2-positive Breast Cancer
Shanghai JMT-Bio Inc.1,800 enrolled1 locationNCT07441460
Recruiting
Phase 2
Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer
University of Chicago85 enrolled4 locationsNCT06291064
Recruiting
Phase 2
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Triple-Negative Breast Carcinoma
Vandana Abramson51 enrolled1 locationNCT07016399
Recruiting
Phase 2
Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
Breast Cancer
Karolinska University Hospital370 enrolled7 locationsNCT05900206
Recruiting
Phase 2
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Breast CancerBreast NeoplasmBreast Tumors
Fudan University716 enrolled1 locationNCT05582499
Recruiting
Phase 2
Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer
HR+/HER2- Breast Cancer
Henan Cancer Hospital357 enrolled1 locationNCT06860529
Recruiting
Phase 2
Guiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived Organoids
Bladder Cancer
Roland Seiler-Blarer34 enrolled1 locationNCT05024734
Recruiting
Phase 2
To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer
Breast Cancer
RemeGen Co., Ltd.79 enrolled1 locationNCT06389006
Recruiting
Phase 2
Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy
Breast Neoplasms
wang shusen116 enrolled1 locationNCT05978648
Recruiting
Phase 1
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
Breast Neoplasms
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University24 enrolled1 locationNCT06121570
Recruiting
Phase 1Phase 2
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
Breast Neoplasms
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University196 enrolled1 locationNCT05981014
Recruiting
Phase 3
EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer
HER2 Positive Early Breast Cancer
Fudan University1,406 enrolled1 locationNCT05883852
Recruiting
Phase 3
TCb vs EC-T in High Risk ER+/HER2- Breast Cancer
Hormone Receptor Positive HER-2 Negative Breast Cancer
Fudan University1,736 enrolled1 locationNCT05901428
Recruiting
Phase 2
Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
West China Hospital35 enrolled1 locationNCT05447702
Recruiting
Phase 2
ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016
Acute Lymphoblastic LeukemiaChildhood CancerDown Syndrome
National Hospital Organization Nagoya Medical Center60 enrolled10 locationsNCT03286634
Recruiting
Phase 4
A Study for the Adjuvant Treatment of Breast Cancer
Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University2,413 enrolled1 locationNCT05420467
Recruiting
Phase 4
A Study for the Neoadjuvant Treatment of Breast Cancer
Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University1,576 enrolled1 locationNCT05420454
Recruiting
Phase 2Phase 3
Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer
HER2-negative Breast CancerNeoadjuvant Chemotherapy
Second Affiliated Hospital, School of Medicine, Zhejiang University260 enrolled1 locationNCT04576143